Related Experiment Video
Updated: Sep 2, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Synaptophysin and chromogranin A expression analysis in human tumors
Ria Uhlig1, David Dum1, Natalia Gorbokon1
1Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Neuroendocrine differentiation, marked by synaptophysin and chromogranin A, occurs in many non-neuroendocrine tumors. This differentiation was not significantly linked to tumor aggressiveness across most cancer types studied.
Area of Science:
- Oncology
- Pathology
- Biomarker Research
Background:
- Neuroendocrine neoplasms (NENs) are characterized by the expression of specific markers like synaptophysin and chromogranin A.
- Understanding the expression of these markers in non-neuroendocrine tumors is crucial for accurate diagnosis and classification.
Purpose of the Study:
- To investigate the prevalence and patterns of neuroendocrine marker expression (synaptophysin and chromogranin A) across a wide spectrum of tumor types.
- To evaluate the potential association between neuroendocrine differentiation and clinicopathological parameters of tumor aggressiveness.
Main Methods:
- Immunohistochemistry was employed to analyze synaptophysin and chromogranin A expression in 14,584 tumor samples from 103 tumor types.
- Tissue microarrays were utilized for high-throughput analysis.
- Statistical comparisons were made between marker expression and clinico-pathological parameters, including tumor stage, grade, and patient outcome.
Main Results:
- Synaptophysin and/or chromogranin A were positive in 96.7% of neuroendocrine neoplasms.
- In non-neuroendocrine tumors (6.3% of samples), neuroendocrine differentiation was observed in various entities, notably skin basal cell carcinomas and adrenocortical carcinomas.
- While neuroendocrine differentiation was common in some adenocarcinomas (female genital tract, pancreatico-/hepato-/biliary tract, prostate), it was rare in urothelial and squamous cell carcinomas. In breast cancer, synaptophysin positivity correlated with advanced stage, high grade, and loss of estrogen receptor expression, but not patient outcome.
Conclusions:
- Neuroendocrine differentiation is a phenomenon observed in a diverse range of non-neuroendocrine tumors.
- The study found no statistically significant association between neuroendocrine differentiation and tumor aggressiveness across most cancer types.
- Synaptophysin expression in breast cancer warrants further investigation regarding its specific implications.
More Related Videos
05:45Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023